Abstract
Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.
Keywords
allopregnanolonePMDDpsychopharmacology
Access This Article
Choose an access option below to view the full article.
How to Cite
Ahmed Naguy, Adel El-Sheshai, Sri Haricharan Thiguti, Bibi Alamiri. Psychopharmacotherapy of Premenstrual Dysphoric Disorder—New Vistas. Psychopharmacology Bulletin.
2022/06/27; 52(3):81-83.
https://doi.org/10.64719/pb.4447